The Russian Ministry of Health approved Coronavir, the third domestic drug from COVID-19 with the international nonproprietary name favipiravir. The first drug, Avifavir, and the second one, Areplivir, were approved in May and June, respectively, RIA News reports.
A new drug from coronavirus can be used only in a hospital setting. It is noted that the drug was registered according to the procedure intended for use in conditions of the threat of emergence and liquidation of emergency situations. Among its contraindications are severe renal and hepatic insufficiency, pregnancy or pregnancy planning, as well as the period of breastfeeding. The drug should not also be used by people under 18 years of age.